| Hazard Information | Back Directory | [Uses]
Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC)[1][2][3]. | [References]
[1] Falchook G S, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)[J]. 2022.
[2] Markham A. Dostarlimab: First Approval. Drugs. 2021 Jul;81(10):1213-1219. DOI:10.1007/s40265-021-01539-5
[3] Kuang Z, et al. A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy. Antib Ther. 2020 Nov 9;3(4):227-236. DOI:10.1093/abt/tbaa022
[4] Sun CY, et al. T cell exhaustion drives osteosarcoma pathogenesis. Ann Transl Med. 2021 Sep;9(18):1447. DOI:10.21037/atm-21-3928 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|